A total of 16 controlled clinical trials of rAd-p53 (GendicineTM) have been carried out for the treatments of advanced cancers, including head and neck cancer, hepatic cell carcinoma, NSCLC, malignant glioma, and epithelial ovarian carcinoma [22,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38] (Table 1). The gene discussed is TP53; the disease is non-small cell lung carcinoma.